Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Robert Pirker, Felix J.F. Herth, Keith M. Kerr et al. · Journal of Thoracic Oncology · 2010
Cited by 284 works. doi:10.1097/jto.0b013e3181f1c8de Open-access PDF
Authors
- Robert Pirker
- Felix J.F. Herth
- Keith M. Kerr
- Martin Filipits
- Miquel Tarón
- David R. Gandara
- Fred R. Hirsch
- Dominique H Grunenwald
- Helmut Popper
- Egbert Frederik Smit
- Manfred Dietel
- Antonio Marchetti
- Christian Manegold
- Peter Schirmacher
- Michael Thomas
- Rafael Rosell
- Federico Cappuzzo
- Rolf Arno Stahel
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers